967. PK/PD Considerations for Vancomycin and Daptomycin
Session: Symposium: Dosing Antibiotics in Critically Ill Patients
Friday, October 6, 2017: 11:20 AM
Room: 06AB
Michael J. Rybak, PharmD, MPH, PhD, Anti-Infective Research Laboratory, Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, MI


Disclosures:

M. J. Rybak, Allergan: Consultant and Grant Investigator , Consulting fee and Speaker honorarium
Merck: Consultant and Grant Investigator , Consulting fee and Grant recipient
NIH: Grant Investigator , Grant recipient
Achaogen: Consultant , Consulting fee
The Medicine Company: Consultant and Grant Investigator , Consulting fee , Grant recipient and Speaker honorarium
Accelerate: Consultant and Grant Investigator , Consulting fee and Grant recipient
Zavante: Consultant , Consulting fee
Bayer: Consultant and Grant Investigator , Consulting fee , Grant recipient and Speaker honorarium

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.